results of retrospective observational study of adalimumab safety and efficacy in patients with juvenile arthritis and uveitis
Article Quality & Performance Metrics
Readership in this journal
EmergingRanked #7 of 111 articles by views in Biocontrol science
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
Abstract
The article contains results of retrospective observational study of adalimumab safety and efficacy in 67 juvenile arthritis and juvenile arthritis with eye involvement patients refractory to classical immunosuppressive treatment. It also contains a description of a recombinant biological medication — adalimumab: already on the 4th week of treatment acute inflammatory changes in the affected joints were relieved, joint motion range fully recovered; by the week 8 — full remission of the uveitis was reported in 45% of affected eyes (27/61), normalized disease activity lab parameters such as ESR, serum C-reactive protein.
Key words: children, juvenile rheumatoid arthritis, rheumatoid uveitis, adalimumab.
(Voprosy sovremennoi pediatrii — Current Pediatrics. — 2011; 10 (6): 96–102)
| Reference Key |
alexeeva2011voprosyresults
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Е.I. Alexeeva;Е.V. Mitenko;Т.М. Bzarova;S.I. Valieva;А.М. Chomakhidze;K.B. Isaeva;Е.G. Chistyakova;R.V. Denisova;T.V. Sleptsova;Т.Yu. Polyaeva;А.N. Fetisova |
| Journal | Biocontrol science |
| Year | 2011 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.